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Background: According to international guidelines, the goal of asthma management is to achieve and maintain
control of the disease, which can be assessed using composite measures. Prospective studies are required to
determine how these measures are associated with asthma outcomes and/or future risk. The ‘InternationaL
cross-sectIonAl and longItudinal assessment on aSthma cONtrol (LIAISON)’ observational study has been designed to
evaluate asthma control and its determinants, including components of asthma management.
Methods/design: The LIAISON study will be conducted in 12 European countries and comprises a cross-sectional
phase and a 12-month prospective phase. Both phases will aim at assessing asthma control (six-item Asthma
Control Questionnaire, ACQ), asthma-related quality of life (Mini Asthma Quality of Life Questionnaire, Mini-AQLQ),
risk of non-adherence to treatment (four-item Morisky Medication Adherence Scale, MMAS-4), potential reasons for
poor control, treatment strategies and associated healthcare costs.
The cross-sectional phase will recruit > 8,000 adult patients diagnosed with asthma for at least 6 months and
receiving the same asthma treatment in the 4 weeks before enrolment.
The prospective phase will include all patients with uncontrolled/poorly controlled asthma at the initial visit to
assess the proportion reaching control during follow-up and to examine predictors of future risk. Visits will take
place after 3, 6 and 12 months.
Discussion: The LIAISON study will provide important information on the prevalence of asthma control and on the
quality of life in a broad spectrum of real-life patient populations from different European countries and will also
contribute to evaluate differences in management strategies and their impact on healthcare costs over 12 months
of observation.
Trial registration: ClinicalTrials.gov identifier, NCT01567280
Keywords: Asthma control, ACQ, LIAISON, Observational study, Quality of life, Patient reported outcomesBackground
Asthma is a serious global health problem with an
increasing prevalence worldwide. People of all ages are
affected by this chronic airways disorder that, when
uncontrolled, can place severe limits on daily life and is
sometimes life threatening or even fatal [1]. A consen-
sus recently stated that there are 300-million people
suffering asthma worldwide [2]. Very recently, the costs* Correspondence: g.nicolini@chiesi.com
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reproduction in any medium, provided the orof persistent asthma have been estimated as EURO
19.3-billion in the whole European population aged
from 15 to 64 years, with a mean total cost per patient
ranging from EURO 509 in controlled asthma up to
EURO 2,281 in uncontrolled asthma [3].
Asthma control is a central focus of the Global Initiative
for Asthma (GINA) Guidelines [1], in which clinicians are
encouraged to concentrate on its assessment based on the
clinical manifestations of disease: symptoms, lung function
and the presence or history of exacerbations [4]. Since
2006, GINA guidelines recommend to classify patientsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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matics, and highlight that the best way to achieve asthma
control is through inhaled anti-inflammatory therapy,
monitoring and asthma education [1]. The assessment of
asthma control should include not only control of the
clinical manifestations but also control of the expected fu-
ture risk to the patient such as exacerbations, accelerated
lung-function decline and side effects of treatments [1].
Treatment of asthma should aim at achieving and
maintaining disease control for prolonged periods with a
minimum amount of medications, with due regard to
the tolerability of treatment, potential for adverse effects,
and costs. Effective therapies are now available, and
allow attaining asthma control in the majority of patients
in randomised controlled trials [5].
However, the proportion of patients lacking asthma con-
trol remains high in both adults and children, reflecting
a significant gap between what treatments can achieve and
the real-life situation [6-10], even in patients receiving
regular treatment with inhaled corticosteroids [11,12].
Well-validated self-assessment questionnaires have
been developed to monitor the level of asthma control,
such as the Asthma Control Questionnaire (ACQ) [13]
and the Asthma Control Test (ACT) [14]. These in-
struments measure asthma symptoms, limitation of
activities and need for rescue medication, and have
been used in most of the recently published surveys on
asthma control.
Country-specific or multinational studies based on
the ACQ or the ACT have shown an uneven situation
of the asthma control in Europe. In a recent study car-
ried out in the Netherlands [15], the percentage of pa-
tients with partly controlled or uncontrolled asthma
evaluated with the ACQ was 35.5% and 27.0%, respect-
ively. In another study performed in five European
countries [16], approximately half of asthmatic sub-
jects were not well controlled according to the ACT
score, and no substantial improvement was found in a
more recent survey conducted in the same countries
[17]. Conversely, a recent observational study carried out
in Italy [18] showed that only 15.8% and 19.8% of patients
referred to respiratory medicine centres had partly con-
trolled or uncontrolled asthma, respectively, based on the
ACT score. These results confirm previous evidence from
a survey conducted in Italy showing that 64.7% of patients
with asthma are well controlled [19].
Other studies have evaluated the level of asthma con-
trol using different methods of assessment, such as pa-
tients’ perception of symptoms [6,20], a questionnaire
based on asthma symptoms and recent history [21], and
the GINA classification of controlled, partly controlled
and uncontrolled asthma [12]. Overall, the results of
these studies indicated a suboptimal level of asthma
control and variability in the prevalence of controlledpatients among European countries [12] or worldwide
macro-areas [6].
Most of the observational studies performed until
now comprised relatively small populations unrepre-
sentative of the asthmatic population of the countries
in which they were performed. In addition, they were
mainly based on a cross-sectional design, which does
not allow assessing the level of asthma control over
time and the impact of adherence to treatment. Fur-
thermore, the limitations due to heterogeneity among
methods for assessment of asthma control such as tele-
phone interviews, web-based questionnaires or postal
questionnaires, do not allow reaching firm conclusions
on patients’ attitudes to asthma management, adher-
ence, level of asthma control and its impact on patients’
quality of life in Europe. The identification of major
reasons for a suboptimal asthma control can help the
physician to optimise asthma management and the
patient to improve his/her perception of the disease.
Based on this background, the ‘InternationaL cross-
sectIonAl and longItudinal assessment on aSthma cON-
trol (LIAISON)’ study has been designed to include a
cross-sectional phase and a 12-month prospective
phase in order to estimate the level of asthma control
in real life, its determinants and its changes during a
1-year follow up.
Objectives
Table 1 summarises the primary and secondary objectives
of the study. The primary objectives of the cross-sectional
phase are to evaluate the proportions of patients with con-
trolled, partly controlled and uncontrolled asthma, and to
assess the health-related quality of life and the factors
associated with asthma control in a real-life population of
asthmatic patients.
The primary objectives of the prospective phase
(which will include only patients with uncontrolled
and partly controlled asthma classified according to
the six-item ACQ score) are to evaluate the propor-
tions of uncontrolled/partly controlled patients reaching
asthma control after 12 months from the cross-sectional
phase visit, to assess the health-related quality of life
and the factors associated with gain of asthma control as
well as predictors of those who are at future risk of
exacerbations.
Methods/design
Study design
Figure 1 shows the design of the cross-sectional phase
and the prospective phase of the study. Subjects satis-
fying entry criteria will be evaluated in the cross-sectional
phase of the study. Asthmatic patients with uncontrolled/
partly controlled asthma will be followed for the 12-
month prospective phase. Follow-up visits will take
Table 1 Primary and secondary objectives to be investigated
Cross-sectional phase Longitudinal phase
Primary
objectives
• Prevalence of patients with controlled or
uncontrolled/partly controlled asthma
• Proportions of patients with controlled, partly controlled and uncontrolled
asthma after 12 months from the cross-sectional phase visit
• Health-related quality of life • Proportion of patients with uncontrolled/partly controlled asthma switching to
controlled asthma after 12 months from the cross-sectional phase visit
• Factors associated with asthma control
• Changes in quality of life after 12 months
• Factors associated with the gain of asthma control
Secondary
objectives
• Proportion of asthmatic smokers and their level
of asthma control
• Association between (current) level of asthma control and (future) risk of
exacerbations
• Antiasthmatic therapies • Relation between change in asthma control and change in rate of exacerbations
during the longitudinal phase (including stratified analyses according to GINA
treatment level)
• Medication adherence • Antiasthmatic therapies
• Healthcare costs over 3 months before the
cross-sectional phase visit
• Proportion of patients with uncontrolled/partly controlled asthma that reach
control after 3 and 6 months from cross-sectional phase visit
• Rate of severe exacerbations in the last 12
months before the cross-sectional phase visit
• Medication adherence
• Reasons for poor control according to the
Investigators’ and the patients’ opinion
• Healthcare costs
• Lung function parameters, if available • Rate of severe exacerbations and the time to first severe exacerbation
• Reasons for poor control according to the Investigators’ and the patients’
opinion
• Lung function parameters, if available
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sectional phase visit.
Study population
The study population will include approximately 8,150
patients attending about 160 outpatient hospitals or
General Practice clinics distributed across 12 European
countries (Austria, Belgium, France, Germany, Greece,
Hungary, Italy, the Netherlands, Poland, Spain, Turkey
and the United Kingdom). At least 400 patients in about
eight centres will be enrolled in each participating coun-
try. Consecutive patients visiting the centre during the
estimated 12-month recruitment period will be enrolled.
Male and female adult (aged ≥18 years) patients with a
clinical diagnosis of asthma (according to GINA guidelines
and confirmed by a chest physician) for at least 6 months,Figure 1 Study design.and receiving the same antiasthmatic drugs in the last
4 weeks before enrolment, will be eligible for study partici-
pation after signing the informed consent.
Patients participating in a clinical trial within the pre-
vious 4 weeks or patients suffering from conditions and
illnesses that might interfere with the study purpose,
according to the investigator’s evaluation, will be ex-
cluded from the study.
Outcome measures
Information on demographic data, smoking habits, oc-
cupational status, professional exposure to asthma risk
factors/triggers, concomitant diseases and therapies and
asthma history will be collected during the first visit.
Due to the observational nature of the study, the spi-
rometry is not included in the study procedures but it
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If available, the lung function parameters will be col-
lected in the case report form. The following self-
administered tools will be used for the assessment of
asthma control, quality of life and adherence to therapy.Six-item asthma control questionnaire (ACQ)
The six-item ACQ [13] includes a measure of the top
five asthma symptoms (woken at night by symptoms,
day-time symptoms, limitation of daily activities, short-
ness of breath and wheeze) and the use of quick-relief
bronchodilators. The asthma control level will be eva-
luated according to the following thresholds: controlled
asthma: ACQ score ≤ 0.75; partly controlled asthma:
0.75 < ACQ score <1.5; uncontrolled asthma: ACQ
score ≥ 1.5.
As long as many factors are to be considered when a
symptom-based approach is being used to achieve optimal
disease control [22], the possible reasons for poor control
(e.g. comorbidities, seasonal worsening, depression, etc.)
will be collected both according to the doctors’ and
patients’ opinions using a multiple choice system from a
drop down list.Mini asthma quality of life questionnaire (mini-AQLQ)
The mini-AQLQ [23] has been developed to measure
the impact of asthma and its treatment that are most
troublesome to adults with asthma according to the
patient’s perspective and contains 15 questions in four
domains: symptoms, activity limitation, emotional func-
tion and environmental stimuli. The overall score ranges
from 7 (indicating no impairment due to asthma) to 1
(indicating a severe impairment due to asthma).Four-item morisky medication adherence scale (MMAS-4)
The MMAS-4 is a validated scale that estimates the risk
of medication non-adherence and consists of four items
assessing reasons for non-adherence: forgetfulness, care-
lessness, feeling better and feeling worse. The Morisky
score ranges between 0 (highly adherent) and 4 (highly
non-adherent) [24,25].Pharmacological therapies
Due to the observational design of the study, antiasthmatic
treatments prescribed to patients during the study will be
at the discretion of the study physicians according to their
clinical judgment and local standards. Antiasthmatic the-
rapies will be recorded in terms of active ingredient, do-
sage, duration and method of administration. Adverse
drug reactions (ADRs) will be recorded for the entire
study duration according to the local laws of each country.Use of healthcare resources and exacerbations
The number of outpatient visits, hospitalisations and
emergency department visits due to asthma will be
recorded in order to relate the use of healthcare re-
sources to the level of asthma control.
Information on the number of severe exacerbations,
defined as the deterioration in asthma resulting in a hos-
pitalisation or an emergency room visit or the need for
systemic steroids for more than 3 days because of
asthma, will also be collected [26].
Data management
Clinical data will be recorded via Electronic Data Capture
(EDC) using the HyperSuite-Hypernet XMRW system, an
electronic CRF (eCRF). Paper questionnaires (six-item
ACQ, mini AQLQ and MMAS-4) filled in by patients du-
ring the clinic visits will be entered into the clinical data-
base by independent data-entry operators.
Sample size
Based on available data from the literature, the propor-
tion of patients with controlled asthma at initial visit
(defined as an ACQ score ≤ 0.75) is expected to be about
37.5% [15]. Considering that patients with uncontrolled
and partly controlled asthma at the cross-sectional phase
visit will be included in the prospective phase, the per-
centage of patients with controlled asthma at month 12
is expected to be approximately 45% [27].
By enrolling 8,150 patients, it is expected that 5,094
patients should have uncontrolled/partly controlled
asthma at the cross-sectional phase visit. The propor-
tion of patients expected to drop out, for any reason,
during the 12-month longitudinal phase is 20%. There-
fore, 4,075 patients should be evaluable at month 12,
which allows estimating the expected 45% of patients
reaching asthma control at the end of longitudinal
phase with a precision of ± 1.5% (two-sided 95% CI).
With regard to the assessment of quality of life, a
standard deviation (SD) for the Mini AQLQ overall
score of approximately 1.21 units can be estimated from
the literature [28]. If 4,075 patients are evaluable for the
analysis of the Mini AQLQ overall score from the cross-
sectional phase visit, then the distance from the bound-
aries of the two-sided 95% CI to the point estimate will
be 0.037 units. Therefore, considering the expected pa-
tients reaching asthma control at the end of the longitu-
dinal phase, the distance from the boundaries of the
two-sided 95% CI to the point estimate will be 0.055
units.
Statistical analysis
All recorded variables will be tabulated using summary
statistics for continuous variables and frequency tables
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comes will be stratified by country.
Logistic regression analysis will be used to analyse binary
variables (e.g. the association between the asthma control
level and quality of life in the cross-sectional phase). Models
will include confounding factors if identified by the explora-
tory analysis. As measures of association between the re-
sponse variable (e.g. the asthma control level) and the
independent variables, the odds ratios (ORs) with the rela-
tive 95% CI along with the p-value will be reported. For
continuous variables, the estimated OR will be expressed
for a change of c units in the covariate.
The analyses of the results of the longitudinal phase will
be conducted using mixed-effect models (SAS Proc
MIXED) to estimate the means of the changes in the
scores over time from the cross-sectional phase visit.
The healthcare costs will be evaluated by descriptive
analysis, considering the time frames of 3 months before
the cross-sectional phase visit and the longitudinal phase
period.
The number of severe exacerbations in the last 12
months before the cross-sectional phase visit and the
number of severe exacerbations per patient/year at each
visit will be descriptively analysed overall and by level
of asthma control. The rate of severe exacerbations per
patient/year will be calculated as the total number of ex-
perienced severe exacerbations over the longitudinal
phase on total number of days of observation of patients
at risk. The time to first asthma severe exacerbation du-
ring the longitudinal phase will be analysed with the
Kaplan-Meier survival analysis, and their significance by
the log-rank test. Predictors of exacerbations will be
analysed by means of a multivariate logistic model. A step-
wise selection approach will be used to identify the most
significant prognostic factors and to eliminate the unim-
portant ones. Using this methodology, a final predictive
model containing just the important variables will be
created.
Ethics
This trial will be conducted in compliance with the
Declaration of Helsinki (1964 and amendments), Good
Clinical Practices (GCP) and all relevant local laws and
regulations. Patients will give their written informed
consent prior to the start of any study-related proce-
dure and the study protocol has been approved by the
reference Ethics Committee of each participating site
(Additional file 1: Appendix).
Discussion
The aim of the LIAISON study is to estimate the level of
asthma control and quality of life in a European real-life
setting and their evolution during 1 year, using validated
self-administered tools such as the six-item ACQ andMini-AQLQ. Further objectives are: to evaluate the rea-
sons for lack of asthma control, the medication adherence,
the impact of pharmacological treatment, the number of
severe exacerbations and healthcare resources use.
Several real-life asthma studies have been reported
elsewhere but the variability in patients’ samples due to
current treatments, the geographical location and the
criteria for exclusion from study participation has led to
different outcomes in terms of prevalence of asthma
control. Moreover, it is difficult to compare the results
of these studies due to the different methods used in
data collection, which included patient self- or web-
administered questionnaires, office-based or hospital-
based physician consultations [18].
With the inclusion of more than 8,000 patients in the
cross-sectional phase and of more than 4,000 in the longi-
tudinal phase of the study, the LIAISON study will be the
largest naturalistic study ever performed in 12 European
countries to investigate asthma control and the impact of
asthma control on quality of life and future risk of exacer-
bations. Furthermore, the longitudinal phase of the study
will provide important information on the adequacy and
effects of management strategies implemented in each
country to reach control in the following year.
Previous multinational studies carried out in Europe
have shown important differences among countries in
the level of asthma control. Rates of not well-controlled
asthma ranged from 65% in Germany to 40% in Spain [16]
or from 63% in Italy to 41% in France [17]. Among ICS
users, the prevalence of uncontrolled asthma ranged
from 20% in Iceland to 67% in Italy [12]. Differences
in symptoms’ control between Western and Central/
Eastern Europe, with somewhat better outcomes in
Western countries, were also reported [6]. In most of
these studies, assessments were performed by phone-
or mail-transmitted questionnaires based on patient
perception of asthma control and severity of symptoms
[6,12,20], or were internet-based with data obtained
from the European National Health and Wellness Sur-
vey [16,17]. Moreover, all the above studies were cross-
sectional and, therefore, gave no information on the
prospective monitoring of patients with poor asthma
control.
In the LIAISON study, the assessments will be per-
formed during patient visits at the clinics, thus allowing a
real-life asthma management approach based on disease
monitoring. It has been suggested that monitoring out-
comes and taking appropriate action through regular visits
may improve current levels of asthma control. Behavioural
factors such as smoking and non-adherence may reduce
the efficacy of treatment and patient perceptions influence
these behaviours. Under-treatment may also be related to
patient underestimation of the significance of symptoms,
and lack of awareness of achievable control [14].
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asthma control because it is applicable to all adults with
asthma, is considered reliable and reproducible. It has
been fully validated for use in both clinical practice and
clinical trials, and the minimum clinically important dif-
ference has been established [13]. The ACQ also has
strong discriminative properties, i.e. it is able to detect
small differences between patients with different levels
of asthma control and it is very sensitive to within-
patient changes in asthma control over time [27]. The
overall population included in the LIAISON study will
be representative of the European real-life setting. A
sample size of at least 400 patients enrolled in at least
eight centres in each country will also allow reliable
country-specific analyses of data collected in a number
of sites that are representative of the entire National ter-
ritory in all involved countries [6]. Previous reports have
included a limited number of sites [12] or a smaller
number of patients in some countries than in others [6],
while other studies have been performed in sites with
non-homogeneous distribution in the same country [21].
Asthmatic smokers and pregnant women, who are usu-
ally excluded from randomised controlled trials (RCT) in
asthma, will be included in the LIAISON study in order to
obtain a large sample that is as representative as possible
for the real-life asthmatic population in Europe. Smoking
is a critical factor associated with increased risks of not
achieving control, excess mortality, asthma attacks and
exacerbations [22,29]. Within all obstructive respiratory
disorders, asthmatics who smoke represent a substantial
portion that increases with age [30]. Therefore, the non-
exclusion of smokers in previous observational studies
[16,18] may in part explain the increased frequency of
poor asthma control in these studies compared to rates
observed in RCT, and may have led to differences among
countries. One weakness of this study is the requirement
for questionnaire completion and patient consent, which
will tend to bias the data towards those managed in good
clinical settings. On the other hand, the recruitment of
consulting patients could tend to bias towards those who
are uncontrolled. Other important endpoints of the study
will be the description of the reasons for poor control
(from both the patient’s and investigator’s perspectives),
the evaluation of patient adherence to antiasthmatic ther-
apy and the impact of suboptimal asthma control on
healthcare costs. There are limited data available on the
cost-effectiveness of treatment strategies aimed at different
levels of asthma control [31,32] and other local studies in-
vestigating cost-effectiveness of asthma treatment stra-
tegies driven by different target levels of asthma control
are ongoing [33].
To our knowledge, the LIAISON study will be the first
to include both a cross-sectional and a longitudinal
phase to assess asthma control and quality of life in alarge population from a number of European countries.
Therefore, the study will allow obtaining pan-European
data while evaluating among-country differences in care
with consistency and its impact from an economic per-
spective on the different national healthcare systems.
In conclusion, it is expected that the multinational
LIASON study will provide novel data on the level of
asthma control and quality of life in clinical practice in
Europe. The results of the study will contribute to un-
derstanding the reasons for poor asthma control and to
evaluate the proportion of patients with uncontrolled or
partly controlled asthma who achieve asthma control in
a 1-year observation period. Moreover, the study will
provide data on adherence to treatment, number of ex-
acerbations and healthcare resource use, together with
insights into the impact of pharmacological treatment
on both clinical and pharmacoeconomic outcomes.Additional file
Additional file 1: Appendix. Ethics Committees that evaluated the
LIAISON study protocol.
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